Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients
IPF 患者口服表没食子儿茶素-3-没食子酸酯 (EGCG) 的 1 期研究
基本信息
- 批准号:10418169
- 负责人:
- 金额:$ 45.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-20 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAttenuatedBindingBiological MarkersBiologyBiopsyBloodChemistryClinicalClinical TrialsClinical Trials DesignCollagenCollagen Type IConsumptionDataDepositionDevelopmentDiagnosticDiseaseDoseDouble-Blind MethodEnrollmentEnsureEpigallocatechin GallateEpithelialExhibitsFDA approvedFamilyFibrillar CollagenFibroblastsFibrosisFutureGoalsGreen teaHealthHepaticHepatotoxicityHumanImageIn VitroInflammationInterstitial CollagenaseInterstitial Lung DiseasesLOX geneLOXL2 geneLaboratoriesLinkLungMeasuresModelingMolecular ProbesMonitorMusNational Heart, Lung, and Blood InstituteOperative Surgical ProceduresOralPathway interactionsPatientsPharmaceutical PreparationsPhasePhase II Clinical TrialsPhosphotransferasesPhysiologicalPilot ProjectsPirfenidonePlacebo ControlPlacebosPlantsPopulationPositron-Emission TomographyPrincipal InvestigatorProgressive DiseaseProtein-Lysine 6-OxidasePulmonary FibrosisRandomizedRenal functionReportingRoleSafetySerumSignal TransductionStructure of parenchyma of lungSurrogate MarkersTestingTimeTissuesToxic effectantifibrotic treatmentclinical research sitecohortcrosslinkdesigndrug developmenteffective therapyfollow-uphigh throughput screeningidiopathic pulmonary fibrosisin vivoindium-bleomycininhibitorinjuredinnovationinsightintervention costnanomolarnintedanibnovelpatient subsetsperiostinphase 1 studyphase 2 studyphase I trialphase II trialpre-clinicalpreclinical studyresponsesmall moleculetherapeutic targettreatment duration
项目摘要
PROJECT SUMMARY / ABSTRACT
The development of additional therapies for idiopathic pulmonary fibrosis is a pressing human health need. We
have identified epigallocatechin-3-gallate (EGCG), as potent (IC50 ~ 50-100 nM) blocker of TGFβ1 responses
ex vivo and new collagen deposition in vivo in the bleomycin model of pulmonary fibrosis. EGCG is a principal
component of green tea and has been utilized in multiple human studies. We have administered EGCG to
patients with pulmonary fibrosis for two weeks prior to undergoing lung biopsy and demonstrated highly
significant reversal of pro-fibrotic markers in lung tissue and decreases in blood biomarkers of TGFβ1
signaling. However, EGCG has not been given to patients with IPF in the setting of concurrent FDA-approved
IPF therapies and determination of the safety of EGCG in the setting of nintedanib or pirfenidone use is
essential given infrequent report of EGCG associated hepatotoxicity. The overarching goal of this proposal is
to define the safety and optimal dose of EGCG in IPF patients. We will use the R61/R33 mechanism to
conduct a robust randomized controlled Phase I trial to obtain additional critical safety and biomarker data
sufficient to empower a Phase II clinical trial to assess the efficacy of EGCG in IPF patients. A total of 5
cohorts of 10 IPF patients each at 6 clinical sites will be enrolled to receive EGCG. In Aim 1, we will determine
the safety of oral 400 mg and 600 mg EGCG given once daily to IPF patients for 12 weeks concurrent with
nintedanib or pirfenidone. We will also determine if 400 mg or 600 mg EGCG impacts nintedanib or pirfenidone
blood levels, and whether these antifibrotics alter the blood levels of EGCG. Clinical safety, especially
hepatotoxicity, will be monitored closely during the 12 week treatment duration and the 4 weeks of follow-up. In
Aim 2, we will measure the change in levels of prespecified serum biomarkers including COMP, Periostin, and
pro-MMP1 with EGCG treatment to determine if there is an in vivo signal for EGCG effect. Lastly, in Aim 3, we
will utilize the type I collagen-specific PET probe, 68Ga-CBP8 to determine the impact of EGCG in attenuating
lung accumulation. The results of Aim 2 and 3 will provide crucial information as to dose selection. This
proposal leverages the expertise of a multi-principal investigator team that are leaders in fibrosis biology and
clinical trial design, a low cost intervention, and an innovative molecular probe. The totality of this information
will provide key information needed to design a phase II with the ultimate goal of developing much needed IPF
therapies.
项目总结/摘要
特发性肺纤维化的其他疗法的开发是人类健康的迫切需求。我们
已经鉴定出表没食子儿茶素-3-没食子酸酯(EGCG)是TGFβ1反应的有效(IC 50 ~ 50-100 nM)阻断剂
在肺纤维化的博来霉素模型中的离体和体内新胶原沉积。EGCG是一种
这种茶是绿色茶的主要成分,已用于多项人体研究。我们已经给予EGCG,
在接受肺活检前两周患有肺纤维化的患者,
肺组织中促纤维化标志物的显著逆转和TGFβ1血液生物标志物的降低
发信号。然而,在FDA批准的并发症背景下,尚未向IPF患者给予EGCG。
IPF治疗和在尼达尼布或吡非尼酮使用背景下测定EGCG的安全性,
必需的,因为很少报告EGCG相关的肝毒性。本提案的总体目标是
确定EGCG在IPF患者中的安全性和最佳剂量。我们将使用R61/R33机制,
进行一项稳健的随机对照I期试验,以获得额外的关键安全性和生物标志物数据
足以使II期临床试验能够评估EGCG在IPF患者中的疗效。共5
将在6个临床站点招募每组10名IPF患者的队列以接受EGCG。在目标1中,我们将确定
IPF患者口服400 mg和600 mg EGCG每日一次,持续12周,同时
尼达尼布或吡非尼酮。我们还将确定400 mg或600 mg EGCG是否影响尼达尼布或吡非尼酮
血液水平,以及这些抗纤维化药物是否会改变EGCG的血液水平。临床安全性,尤其是
在12周治疗期间和4周随访期间将密切监测肝毒性。在
目的2,我们将测量预先指定的血清生物标志物水平的变化,包括COMP、骨膜蛋白和
pro-MMP 1与EGCG处理以确定是否存在EGCG作用的体内信号。在目标3中,我们
将利用I型胶原特异性PET探针68 Ga-CBP 8来确定EGCG在减弱
肺蓄积目标2和3的结果将为剂量选择提供关键信息。这
该提案利用了多个主要研究者团队的专业知识,这些团队是纤维化生物学的领导者,
临床试验设计、低成本干预和创新的分子探针。这些信息的全部
将提供设计第二阶段所需的关键信息,其最终目标是制定急需的指规数
治疗
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Harold A Chapman其他文献
Harold A Chapman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Harold A Chapman', 18)}}的其他基金
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients
IPF 患者口服表没食子儿茶素-3-没食子酸酯 (EGCG) 的 1 期研究
- 批准号:
10702133 - 财政年份:2022
- 资助金额:
$ 45.38万 - 项目类别:
Program to promote lung regeneration and block fibrosis
促进肺再生和阻止纤维化的计划
- 批准号:
9893639 - 财政年份:2020
- 资助金额:
$ 45.38万 - 项目类别:
Program to promote lung regeneration and block fibrosis
促进肺再生和阻止纤维化的计划
- 批准号:
10570862 - 财政年份:2020
- 资助金额:
$ 45.38万 - 项目类别:
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage
上皮干/祖细胞作为弥漫性肺泡损伤的修复剂
- 批准号:
10181019 - 财政年份:2016
- 资助金额:
$ 45.38万 - 项目类别:
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage
上皮干/祖细胞作为弥漫性肺泡损伤的修复剂
- 批准号:
9355470 - 财政年份:2016
- 资助金额:
$ 45.38万 - 项目类别:
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage
上皮干/祖细胞作为弥漫性肺泡损伤的修复剂
- 批准号:
10418711 - 财政年份:2016
- 资助金额:
$ 45.38万 - 项目类别:
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung
上皮干细胞/祖细胞修复受损肺
- 批准号:
9109038 - 财政年份:2015
- 资助金额:
$ 45.38万 - 项目类别:
Identification, Isolation, and Reprogramming Alveolar Epithelial Progenitor Cells
肺泡上皮祖细胞的鉴定、分离和重编程
- 批准号:
7676645 - 财政年份:2008
- 资助金额:
$ 45.38万 - 项目类别:
Urokinase Receptor Integrin Interactions in Lung Cancer
肺癌中尿激酶受体整合素相互作用
- 批准号:
7318124 - 财政年份:2007
- 资助金额:
$ 45.38万 - 项目类别:
Urokinase Receptor Integrin Interactions in Lung Cancer
肺癌中尿激酶受体整合素相互作用
- 批准号:
8079454 - 财政年份:2007
- 资助金额:
$ 45.38万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 45.38万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 45.38万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 45.38万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 45.38万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 45.38万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 45.38万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 45.38万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 45.38万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 45.38万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 45.38万 - 项目类别:
Idea to Innovation